Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators.

Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.

PMID:
20709233
[PubMed - indexed for MEDLINE]
2.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
[PubMed - indexed for MEDLINE]
3.

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17;353(20):2121-34.

PMID:
16291982
[PubMed - indexed for MEDLINE]
Free Article
4.

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252.

PMID:
16478899
[PubMed - indexed for MEDLINE]
5.

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group.

Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15.

PMID:
18417461
[PubMed - indexed for MEDLINE]
Free Article
6.

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

Hollander P.

Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.

PMID:
17296341
[PubMed - indexed for MEDLINE]
7.

Rimonabant: obituary for a wonder drug.

Boekholdt SM, Peters RJ.

Lancet. 2010 Aug 14;376(9740):489-90. doi: 10.1016/S0140-6736(10)61080-X. No abstract available.

PMID:
20709215
[PubMed - indexed for MEDLINE]
8.

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370.

PMID:
15836887
[PubMed - indexed for MEDLINE]
9.

The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.

Kintscher U.

Eur Heart J. 2008 Jul;29(14):1709-10. doi: 10.1093/eurheartj/ehn255. Epub 2008 Jun 13. No abstract available.

PMID:
18556715
[PubMed - indexed for MEDLINE]
Free Article
10.

Rimonabant: new data and emerging experience.

Wright SM, Dikkers C, Aronne LJ.

Curr Atheroscler Rep. 2008 Feb;10(1):71-8. Review.

PMID:
18366988
[PubMed - indexed for MEDLINE]
11.

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group.

Lancet. 2006 Nov 11;368(9548):1660-72. Erratum in: Lancet. 2006 Nov 11;368(9548):1650.

PMID:
17098084
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.

Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258.

PMID:
18227491
[PubMed - indexed for MEDLINE]
13.

[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].

Boekholdt SM, Jukema JW, Peters RJ.

Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. Review. Dutch.

PMID:
18161262
[PubMed - indexed for MEDLINE]
14.

[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].

[No authors listed]

MMW Fortschr Med. 2007 Jun 28;149(27-28):8. German. No abstract available.

PMID:
17717874
[PubMed - indexed for MEDLINE]
15.

Rimonabant: endocannabinoid inhibition for the metabolic syndrome.

Wierzbicki AS.

Int J Clin Pract. 2006 Dec;60(12):1697-706. Review. Erratum in: Int J Clin Pract. 2007 Mar;61(3):534.

PMID:
17109677
[PubMed - indexed for MEDLINE]
16.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

PMID:
18426513
[PubMed - indexed for MEDLINE]
17.

Effect of rimonabant on weight reduction and cardiovascular risk.

van Oosten B, Killestein J, Polman Ch.

Lancet. 2005 Jul 30-Aug 5;366(9483):368-9; author reply 369-70. No abstract available.

PMID:
16054933
[PubMed - indexed for MEDLINE]
18.

[Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].

Chatterjee T, Ritz A, Ince H, Nienaber ChA, Rehders TC.

Praxis (Bern 1994). 2008 May 28;97(11):613-21. German.

PMID:
18592956
[PubMed - indexed for MEDLINE]
19.

Effect of rimonabant on weight reduction and cardiovascular risk.

Hirschel B.

Lancet. 2005 Jul 30-Aug 5;366(9483):369; author reply 369-70. No abstract available.

PMID:
16054934
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk